AbbVie, Inc. (NYSE:ABBV) announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA (adalimumab) as a treatment for fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis, an area of unmet need. Currently there are no approved treatments for fingernail psoriasis. AbbVie Inc (NYSE:ABBV) stock performance was 1.07% in last session and finished the day at … Continue reading Trader’s Alert: AbbVie Inc (NYSE:ABBV), NeoStem Inc (NASDAQ:NBS), Occidental Petroleum Corporation (NYSE:OXY), Wells Fargo & Co (NYSE:WFC)